SCHEMBL6489466

SCHEMBL6489466

O=C(O)C1=C(c2ccc(C(F)(F)F)cc2)CCCCCC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 3/20 0.52
PTGS2 P35354 2/20 0.49
PTGS1 P23219 1/20 0.49
SLC6A3 Q01959 4/20 0.48
SLC6A4 P31645 1/20 0.48
LMNA P02545 1/20 0.47
SRD5A2 P31213 2/20 0.43
MEN1 O00255 1/20 0.41
HPGD P15428 1/20 0.41
TSHR P16473 1/20 0.41
KMT2A Q03164 1/20 0.41
KIF11 P52732 2/20 0.41
CYP2C8 P10632 1/20 0.41
PSEN1 P49768 1/20 0.41
PSEN2 P49810 1/20 0.41
APH1B Q8WW43 1/20 0.41
NCSTN Q92542 1/20 0.41
APH1A Q96BI3 1/20 0.41
PSENEN Q9NZ42 1/20 0.41
CES2 O00748 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6489462 1.00 SLC6A2 (0.52) SLC6A2PTGS2PTGS1SLC6A3SLC6A4
SCHEMBL6492770 1.00 SLC6A2 (0.52) SLC6A2PTGS2PTGS1SLC6A3SLC6A4
SCHEMBL6488184 1.00 SLC6A2 (0.52) SLC6A2PTGS2PTGS1SLC6A3SLC6A4
SCHEMBL6498616 0.97 PTGS2 (0.53) SLC6A2PTGS2PTGS1SLC6A3SLC6A4
SCHEMBL6499457 0.83 SLC6A2 (0.77) SLC6A2PTGS2SLC6A3SLC6A4
SCHEMBL6499224 0.81 SLC6A3 (0.51) SLC6A2PTGS2PTGS1SLC6A3SLC6A4
SCHEMBL6503784 0.80 SLC6A2 (0.56) SLC6A2PTGS2SLC6A3SLC6A4MEN1
SCHEMBL6503781 0.80 SLC6A2 (0.56) SLC6A2PTGS2SLC6A3SLC6A4MEN1
SCHEMBL6677499 0.79 NPC1 (0.50) SLC6A2PTGS1LMNAKIF11
SCHEMBL10524688 0.79 SLC6A3 (0.53) SLC6A2SLC6A3SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors DAISO CO., LTD. (JP) 2005-02-17 US disclosed
EP-1472226-A1 HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-11-03 EP disclosed
WO-2003045921-A1 HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-06-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors APOB, APOL1, CTRB2 SLC6A2 1801/4885PTGS2 1252/4885PTGS1 1487/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.